Wednesday, January 21, 2026

Fw: Ref.: (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

 

 

Leprosy Mailing List –   January 21,  2026

 

Ref.:  (LML) Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies - Special Issue

From: Cleverson Teixeira Soares, Patrícia Sammarco Rosa and  Bruno de Carvalho Dornelas, Instituto Lauro de Souza Lima, Bauru, Brazil

____________________________________________________________________________

 



Dear Pieter;

 

I hope you are doing fine and wish you a happy 2026!

 

Could you please help us promoting this special issue again?

 

https://www.mdpi.com/si/230126

 

Special Issue Information

Dear Colleagues,

The Special Issue entitled "Mycobacterium leprae, Mycobacterium lepromatosis and Leprosy Studies" aims to present recent research on a wide range of topics related to leprosy, a complex disease that mainly affects people living in developing countries. People exposed to Mycobacterium leprae or Mycobacterium lepromatosis may develop leprosy.

During the course of the disease, reaction phenomena typical of leprosy often occur, known as type 1 (T1R) and type 2 (T2R). These phenomena aggravate the disease and can cause significant and permanent sequelae. Little is known about the pathophysiological mechanisms of leprosy and its reaction phenomena. In addition, factors inherent to the bacilli and its interaction with the human host, such as energy resources and escape mechanisms, are slowly being revealed.

New studies are important to elucidate the pathophysiology of leprosy and, above all, to bring new approaches to the prevention and treatment of leprosy and leprosy reactions. We encourage the submission of clinical, translational, and basic research on leprosy. Some of its focal points include, but are not limited to, the following:

  1. Serum or tissue markers that may be related to the diagnosis of the disease and reactional episodes.
  2. Therapeutic approaches with commercially known drugs or new drug targets.
  3. Clinical studies evaluating the risks of triggering reactional phenomena.
  4. Metabolomic, transcriptomic, or proteomic profiles that correlate with the leprosy clinical forms and reactional phenomena.

 

Reviews, original research, and communications will be welcome.

Dr. Cleverson Teixeira Soares
Dr. Patrícia Sammarco Rosa
Dr. Bruno de Carvalho Dornelas
Guest Editors

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/7e46c396-a858-4770-88d4-e62bacfbc47an%40googlegroups.com.

No comments: